And according to GSK Chief Financial Officer Simon Dingemans, GSK is expecting growth for the next few quarters "to be a bit more challenging" as competition picks up, he said on the company's Q3 earnings call. RELATED: GSK executives change their tune as AZ, Sanofi heap pressure on respiratory hopeful Nucala On the call, pharma chief Luke Miels—a former AZ executive—tried to inspire investor confidence, saying the company's Nucala had "very much held [Fasenra] in place in Japan and Europe." Miels did acknowledge the threat from Fasenra and Dupixent, but he stressed that it wasn't necessarily about the products themselves, but "about execution."